The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.

ABSTRACT: Cladribine is a purine nucleoside analog initially developed in the 1970s as a treatment for various blood cancers. Due to the molecule's ability to preferentially reduce T and B lymphocytes, it has been developed into an oral formulation for the treatment of multiple sclerosis (MS). The unique proposed mechanism of action of cladribine allows for the therapy to be delivered orally over two treatment-week cycles per year, one cycle at the beginning of the first month and one cycle at the beginning of the second month of years 1 and 2, with the potential for no further cladribine treatment required in years 3 and 4. This review summarizes the clinical development program for cladribine tablets in patients with MS, including the efficacy endpoints and results from the 2-year phase III CLARIT

SUBMITTER: Rammohan K 

PROVIDER: S-EPMC7708385 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature